139 related articles for article (PubMed ID: 34755091)
1. The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas.
Yan X; Zhou Q; Zhu H; Liu W; Xu H; Yin W; Zhao M; Jiang X; Ren C
iScience; 2021 Nov; 24(11):103249. PubMed ID: 34755091
[TBL] [Abstract][Full Text] [Related]
2. SYK Is Associated With Malignant Phenotype and Immune Checkpoints in Diffuse Glioma.
Zhou Q; Wei M; Shen W; Huang S; Fan J; Huang H
Front Genet; 2022; 13():899883. PubMed ID: 35910221
[No Abstract] [Full Text] [Related]
3. Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.
Zhou Q; Yan X; Liu W; Yin W; Xu H; Cheng D; Jiang X; Ren C
Front Oncol; 2020; 10():586019. PubMed ID: 33425739
[TBL] [Abstract][Full Text] [Related]
4. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
5. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.
Wang ZL; Li GZ; Wang QW; Bao ZS; Wang Z; Zhang CB; Jiang T
Oncoimmunology; 2019; 8(2):e1541535. PubMed ID: 30713802
[No Abstract] [Full Text] [Related]
6. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
7. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
[No Abstract] [Full Text] [Related]
8. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional Characteristics of
Chang YZ; Li GZ; Pang B; Zhang KN; Zhang XH; Wang YZ; Jiang ZL; Chai RC
Front Cell Dev Biol; 2020; 8():580464. PubMed ID: 33195221
[No Abstract] [Full Text] [Related]
11. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
12. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
13. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
14. PD-1 related transcriptome profile and clinical outcome in diffuse gliomas.
Liu S; Wang Z; Wang Y; Fan X; Zhang C; Ma W; Qiu X; Jiang T
Oncoimmunology; 2018; 7(2):e1382792. PubMed ID: 29308304
[No Abstract] [Full Text] [Related]
15. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
16. A B7-CD28 Family-Based Signature Demonstrates Significantly Different Prognosis and Immunological Characteristics in Diffuse Gliomas.
Deng X; Chen K; Ren J; Zeng J; Zhang Q; Li T; Tang Q; Zhu J
Front Mol Biosci; 2022; 9():849723. PubMed ID: 35928223
[TBL] [Abstract][Full Text] [Related]
17. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
18. PD-L2 Serves as a Potential Prognostic Biomarker That Correlates With Immune Infiltration and May Predict Therapeutic Sensitivity in Lower-Grade Gliomas.
Xie Q; Huang X; Huang W; Liu F
Front Oncol; 2022; 12():860640. PubMed ID: 35756621
[TBL] [Abstract][Full Text] [Related]
19. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
20. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]